Phase 2 Study of Dasatinib (Sprycel) in Patients With Alveolar Soft,Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid,Sarcoma, or Solitary Fibrous Tumor

About 20% of people with chondrosarcoma responded to the drug (tumor shrinkage by 20%).

On average people with CS were on the drug for about 4-5 months before it was deemed ineffective though.

In looking at the criteria for CS patients on the trial, it looks as if Grade I and II CS were allowed on but not Grade III. That is probably not a big deal given Grade II was allowed on, but it was not tested in Grade III pts in this trial.

I don’t see anything specifically about lung mets in the trial, but again should not make a difference.

The drug is a cousin of imatinib.
cancer 2016 dasatinib.pdf